Europe’s cannabis market is growing quickly and quietly turning into a multi‑billion‑euro business. MMJ Daily has published the key numbers behind Europe’s cannabis market.
The Main Engine is Germany
Germany is the biggest medical cannabis market in Europe, worth more than €670 million in 2025 and expected to reach about €1,3 billion by 2029. Imports doubled in 2024 to 72000 kg, mainly from Canada, Portugal, and Denmark, while local growers are expanding under a licensing system.
More supply is pushing prices down: average prices per gram of marijuana fell from €10 to €7 in one year, although cannabis flower still accounts for around 86% of products. At the same time, more than 230 cannabis clubs now operate under Germany’s CanG law, and 28 districts in 10 states have applied to run adult‑use pilot shops.
UK: Growing with Digitalization
The UK is Europe’s second‑largest medical cannabis market, valued at more than €300 million and expected to reach about €630 million by 2029. More than 30 telehealth platforms help patients get prescriptions online, making digital access central to how the system works.
Imports of cannabis remain high, jumping from under 3 tons before 2022 to 15 tons in 2024. Local cultivation is catching up as well.
Average flower prices are relatively stable around €8 per gram, which suggests strong demand even as supply grows. Analysts note that the market is moving from niche to mainstream, creating space for both global brands and local players.
Poland, Denmark, Czech Republic: Export Players
Poland has become Europe’s fourth‑largest medical cannabis market, projected at €72 million in 2025, supported by telemedicine and new product approvals. The Czech Republic has sharply increased exports, sending 1300 kilograms to Germany in 2024 after updating its cultivation rules.
Denmark has turned its pilot program into a permanent scheme and exported more than 7 tons of medical cannabis to Germany in 2024. Together, these countries are building a strong export base that feeds Europe’s largest medical markets.
Switzerland: Legalization Test-Drive
Switzerland is running some of the most advanced adult‑use trials. Since 2023, its pilot projects have enrolled more than 10 000 participants across seven studies. Early results show no increase in overall consumption, but participants report safer products and less reliance on illegal markets.
Sales from the pilots were expected to reach about €24 million by the end of 2025. A draft bill for nationwide legalization has already passed a key committee stage, with a final vote planned for 2026, making Switzerland one of the most important countries to watch in Europe’s cannabis story.
Across Europe, cannabis is being reshaped by new rules, rising patient numbers, and expanding exports. Germany and the UK lead the medical market, Poland, Denmark, and the Czech Republic are building export strength, and Switzerland is testing what full legalization could look like. Together, they show how fast Europe’s cannabis economy is changing — and how much bigger it could become in the next few years.
